322 related articles for article (PubMed ID: 24507957)
1. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment.
Wissing KM; Pipeleers L
Transplant Rev (Orlando); 2014 Apr; 28(2):37-46. PubMed ID: 24507957
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic disorders in renal transplant recipients].
Mikolasević I; Jelić I; Sladoje-Martinović B; Orlić L; Zivcić-Cosić S; Vuksanović-Mikulicić S; Mijić M; Racki S
Acta Med Croatica; 2012 Jul; 66(3):235-41. PubMed ID: 23441539
[TBL] [Abstract][Full Text] [Related]
3. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.
Claes K; Meier-Kriesche HU; Schold JD; Vanrenterghem Y; Halloran PF; Ekberg H
Nephrol Dial Transplant; 2012 Feb; 27(2):850-7. PubMed ID: 21617197
[TBL] [Abstract][Full Text] [Related]
4. Metabolic disorders following kidney transplantation.
Phillips S; Heuberger R
J Ren Nutr; 2012 Sep; 22(5):451-60.e1. PubMed ID: 22445053
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression and metabolic syndrome in renal transplant recipients.
Lo A
Metab Syndr Relat Disord; 2004; 2(4):263-73. PubMed ID: 18370695
[TBL] [Abstract][Full Text] [Related]
7. Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation.
Nagaraja P; Ravindran V; Morris-Stiff G; Baboolal K
Transpl Int; 2013 Mar; 26(3):273-80. PubMed ID: 23230898
[TBL] [Abstract][Full Text] [Related]
8. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y; Bresnahan B; Campistol J; Durrbach A; Grinyó J; Neumayer HH; Lang P; Larsen CP; Mancilla-Urrea E; Pestana JM; Block A; Duan T; Glicklich A; Gujrathi S; Vincenti F
Transplantation; 2011 May; 91(9):976-83. PubMed ID: 21372756
[TBL] [Abstract][Full Text] [Related]
9. Issues of obesity in kidney transplantation.
Kent PS
J Ren Nutr; 2007 Mar; 17(2):107-13. PubMed ID: 17321949
[TBL] [Abstract][Full Text] [Related]
10. Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Ward HJ
J Ren Nutr; 2009 Jan; 19(1):111-22. PubMed ID: 19121784
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant diabetes mellitus. The role of immunosuppression.
Jindal RM; Sidner RA; Milgrom ML
Drug Saf; 1997 Apr; 16(4):242-57. PubMed ID: 9113492
[TBL] [Abstract][Full Text] [Related]
12. Evaluating mechanisms of post-transplant diabetes mellitus.
van Hooff JP; Christiaans MH; van Duijnhoven EM
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi8-vi12. PubMed ID: 15575024
[TBL] [Abstract][Full Text] [Related]
13. Costimulation blockade with belatacept in renal transplantation.
Vincenti F; Larsen C; Durrbach A; Wekerle T; Nashan B; Blancho G; Lang P; Grinyo J; Halloran PF; Solez K; Hagerty D; Levy E; Zhou W; Natarajan K; Charpentier B;
N Engl J Med; 2005 Aug; 353(8):770-81. PubMed ID: 16120857
[TBL] [Abstract][Full Text] [Related]
14. Improving long-term renal transplant outcomes with tacrolimus: speculation vs evidence.
First MR
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi17-vi22. PubMed ID: 15575022
[TBL] [Abstract][Full Text] [Related]
15. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Valantine H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
[TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy.
Sato T; Inagaki A; Uchida K; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Tominaga Y; Okajima Y; Ohta K; Suga H; Taguchi S; Kakiya S; Itatsu T; Kobayashi T; Nakao A
Transplantation; 2003 Nov; 76(9):1320-6. PubMed ID: 14627910
[TBL] [Abstract][Full Text] [Related]
17. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
19. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM).
Kuypers DR; Claes K; Bammens B; Evenepoel P; Vanrenterghem Y
Nephrol Dial Transplant; 2008 Jun; 23(6):2033-42. PubMed ID: 18174264
[TBL] [Abstract][Full Text] [Related]
20. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
